Registered title, quoted from ClinicalTrials.gov
Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
An open trial on multiple myeloma, registered on ClinicalTrials.gov. Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07169500, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 50 years; sex: all
Registered eligibility fields
Congestive heart failure (New York Heart Association [NYHA] class III or IV), NYHA scores are in Appendix 2
Exclusion criterion 7
Malignant tumors other than multiple myeloma within 3 years prior to signing the ICF, except fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical surgery, ductal carcinoma in situ of the breast after radical surgery, and other in situ cancers at other sites one year after radical surgery, provided there is no ongoing treatment and no signs of recurrence during the screening period;
Exclusion criterion 10
ECOG score of 0-1, see Appendix 5 for ECOG scoring;
Inclusion criterion 14
Serum total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN)
Inclusion criterion 4
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN
Inclusion criterion 5
Creatinine clearance (CrCl) (Cockcroft-Gault formula) ≥ 40 ml/min
Inclusion criterion 6
Prothrombin time (PT) ≤ 1.5 × ULN, activated partial thromboplastin time (APTT) < 1.5 × ULN, international normalized ratio (INR) < 1.5 × ULN
Inclusion criterion 7
Hemoglobin (Hb) ≥ 60 g/L
Inclusion criterion 8
Absolute neutrophil count (ANC) ≥ 1.0 × 10\^9/L (no granulocyte colony-stimulating factor [G-CSF] or other growth factors received within 7 days prior to screening laboratory tests)
Inclusion criterion 9
Platelets (PLT) ≥ 50 × 10\^9/L (no platelet transfusion received within 7 days prior to screening laboratory tests)
Inclusion criterion 11
Peripheral blood hepatitis B virus (HBV) DNA test value is above the detection limit
Exclusion criterion 14
Hepatitis C virus (HCV) antibody positive and peripheral HCV-RNA positive
Exclusion criterion 15
Human immunodeficiency virus (HIV) antibody positive
Exclusion criterion 16
Female participants of childbearing potential must have a negative pregnancy test and not be breastfeeding; female or male participants of childbearing potential must use effective contraceptive methods or devices for 24 months after cell infusion.
Inclusion criterion 16
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07169500, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria: Young female, 18-55 years old;
- Subjects voluntarily participate in the study and sign the informed consent form (ICF) themselves or through their legal guardian;
- Confirmed diagnosis of multiple myeloma through flow cytometry or immunohistochemistry;
- Subjects must have adequate organ function and meet all of the following test results:
- Serum total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN)
- Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN
- Creatinine clearance (CrCl) (Cockcroft-Gault formula) ≥ 40 ml/min
- Prothrombin time (PT) ≤ 1.5 × ULN, activated partial thromboplastin time (APTT) < 1.5 × ULN, international normalized ratio (INR) < 1.5 × ULN
- Hemoglobin (Hb) ≥ 60 g/L
- Absolute neutrophil count (ANC) ≥ 1.0 × 10\^9/L (no granulocyte colony-stimulating factor [G-CSF] or other growth factors received within 7 days prior to screening laboratory tests)
- Absolute lymphocyte count (ALC) ≥ 0.5 × 10\^9/L
- Platelets (PLT) ≥ 50 × 10\^9/L (no platelet transfusion received within 7 days prior to screening laboratory tests)
- Left ventricular ejection fraction (LVEF) ≥ 45%
- Blood oxygen saturation (SpO2) ≥ 92%
- ECOG score of 0-1, see Appendix 5 for ECOG scoring;
- Expected survival ≥ 3 months;
- Female participants of childbearing potential must have a negative pregnancy test and not be breastfeeding; female or male participants of childbearing potential must use effective contraceptive methods or devices for 24 months after cell infusion.
Exclusion Criteria:
- History of allergy to any component of the cellular product;
- Severe heart disease, including but not limited to:
- Myocardial infarction, coronary angioplasty, or stent implantation within 6 months prior to signing the ICF
- Unstable angina
- Severe arrhythmia
- History of severe non-ischemic cardiomyopathy
- Congestive heart failure (New York Heart Association [NYHA] class III or IV), NYHA scores are in Appendix 2
- Stroke or seizure within 6 months prior to signing the ICF;
- Autoimmune diseases, immunodeficiency, or other conditions requiring immunosuppressive therapy;
- Malignant tumors other than multiple myeloma within 3 years prior to signing the ICF, except fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical surgery, ductal carcinoma in situ of the breast after radical surgery, and other in situ cancers at other sites one year after radical surgery, provided there is no ongoing treatment and no signs of recurrence during the screening period;
- Presence of uncontrolled active infection;
- Unstable systemic diseases as judged by the investigator, including but not limited to severe liver, kidney, or metabolic diseases requiring medication.
- Within one week before lymphocyte collection, the storage device falls under any of the following conditions:
- Peripheral blood hepatitis B virus (HBV) DNA test value is above the detection limit
- Hepatitis C virus (HCV) antibody positive and peripheral HCV-RNA positive
- Human immunodeficiency virus (HIV) antibody positive
- Syphilis antigen or antibody positive
- CMV-DNA positive
- Within one week before lymphocyte collection, use of more than 5 mg/day of prednisone (or an equivalent dose of other corticosteroids);
- Prior use of any CAR-T cell products or other genetically modified T cell therapies;
- Prior BCMA-targeted therapy;
- Vaccination with a live vaccine within 4 weeks before signing the ICF;
- History of alcoholism, drug abuse, or psychiatric disorders; Other conditions that the investigator deems unsuitable for participation in this study.
Quoted from ClinicalTrials.gov, NCT07169500, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07169500, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.